Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis

@article{Farris2017PharmacodynamicsOC,
  title={Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis},
  author={Manuela Farris and Carlo Bastianelli and Elena Rosato and Ivo Brosens and Giuseppe Benagiano},
  journal={Expert Review of Clinical Pharmacology},
  year={2017},
  volume={10},
  pages={1129 - 1144}
}
ABSTRACT Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Recent information on the effect of androgens, estrogens, progestins, as well as various COC combinations on the coagulation cascade will be reviewed aiming at providing an updated picture. The present article reviews… 
Pharmacodynamics of combined estrogen–progestin oral contraceptives: 4. Effects on uterine and cervical epithelia
TLDR
Overall, combined oral contraceptives (COCs) inhibit normal proliferative changes and the endometrium becomes thin, narrow, with widely spaced glands and pre-decidual changes in the stroma.
Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study
  • S. Palacios, E. Colli, P. Regidor
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
TLDR
The results confirm the beneficial properties of the drospirenone-only pill on a variety of metabolic parameters and on coagulatory parameters, and there was no impact on hemostasis.
Estetrol: A New Choice for Contraception
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent research has demonstrated that it is a potent, orally bioavailable, natural selective estrogen
Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study
TLDR
Reduced antigen and activity levels of PS and antithrombin and increased activity level of PC were observed even during the first cycle of low-dose COC use, and the effects on PS and PC activities were also observed in the hormone-free interval.
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
TLDR
Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquiredThrombophilia.
Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study
  • S. Reed, C. Koro, +4 authors K. Heinemann
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
TLDR
NOMAC-E2 demonstrated superior contraceptive effectiveness compared to COCLNG, likely due to the comparatively short hormone-free interval and possibly reinforced by the long half-life of NOMAC.
A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.
TLDR
There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population.
Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?
TLDR
An analysis from the Atherosclerosis Risk in Communities (ARIC) Study was performed to investigate whether circulating blood levels of endogenous hormones, such as dehydroepiandrosterone sulphate (DHEAS), testosterone and sex hormone-binding globulin (SHBG), were associated with the incidence of VTE in men and post-menopausal women receiving HRT or no HRT.
...
1
2
...

References

SHOWING 1-10 OF 213 REFERENCES
Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism
ABSTRACT Introduction: The risk-benefit profile of any pharmacologic agent must be evaluated against risks connected with the events to be avoided. This is especially true in the case of hormonal
Differential effects of progestins on hemostasis.
TLDR
Progestins seems to have different effects on the hemostatic system due to their different pattern of biological activities, including in the arterial vascular system, where some progestin may reduce the endothelium-dependent vasodilating action of estrogens and stimulate intima proliferation and upregulate thrombin receptor expression while other progestins did not.
Effect of oral contraceptives on haemostasis variables.
TLDR
The role of PGs in the effects of COCs is significant and their design may in addition to reduction of oestrogen dosage be important in reducing haemostatic complications, according to summarised literature data.
Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive
TLDR
The novel COC containing estradiol valerate/dienogest had similar or less pronounced effects on hemostatic parameters than ethinylestradiol/ levonorgestrel.
Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
TLDR
Of particular importance was the finding that coagulation activation, expressed by the levels of thrombin-antithrombin III-complexes, fibrin formation, and the efficacy of fibrinolysis was identical in the two groups, suggesting a correlation between estrogen dose and cardiovascular episodes in oral contraceptive users.
Coagulation effects of oral contraception.
  • J. Bonnar
  • Medicine
    American journal of obstetrics and gynecology
  • 1987
TLDR
Current research is aimed at finding the estrogen/progestogen formulations that induce the least changes in the coagulation system and other physiologic processes, and the new low-dose formulations should reduce the risk of vascular thrombotic complications.
New progestagens for contraceptive use.
TLDR
Several new progestins, including dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG) have been synthesized in the last two decades, designed to have no androgenic or estrogenic actions and to be closer to the physiological hormone P.
Estradiol valerate and dienogest: a new approach to oral contraception
TLDR
Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval.
...
1
2
3
4
5
...